Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC).
M. Gross,J. Soscia,S. Sakowsky,O. Castellanos,D. Agus
DOI: https://doi.org/10.1200/JCO.2009.27.15_SUPPL.5154
IF: 45.3
2009-05-20
Journal of Clinical Oncology
Abstract:5154 Background: Targeting of mTOR and vascular endothelial growth factor (VEGF) alone or with chemotherapy has been reported for CRPC. We report a dose finding study combining mTOR and VEGF inhibitors along with docetaxel for advanced CRPC.
METHODS
Eligible patients (pts) had progressive, metastatic, chemo-naive CRPC. A modified adaptive design was used to explore 3 dose levels. 3 pts were treated in each cohort, expanded by 3 pts if a dose limiting toxicity (DLT) was observed. If no DLT occurred after all pts completed 2 cycles in a cohort, pts were enrolled at the next dose level. If a DLT was seen in 2 pts, that dose level was closed. Dose levels included: cohort 1 (D 75 mg/m2, R 2.5 mg, B 15 mg/kg); cohort 2 (D 75 mg/m2, R 5 mg, B 15 mg/kg); and cohort 3 (D 65 mg/m2, R 5 mg, B 15 mg/kg). D+B was given IV day (d) 1 and R PO days 1-21 on a 21 d cycle. Efficacy is explored as: maximal confirmed PSA decline; partial or complete response (PR+CR) by RECIST criteria; and/or changes in bone scintigraphy.
RESULTS
12 patients have been enrolled to complete the dose-finding phase. Baseline median (range) values include: age 70 (58-78) yrs, PSA 115 (4-1336) ng/mL, alkaline phosphatase 107 (37-763) U/L. All pts had PSA elevations, 5 pts had metastasis to lung and/or lymph nodes. 9 pts had bone metastases. Common toxicities were fatigue and mucositis. DLTs by dose level is summarized as: cohort 1, DLT in 1 of 6 pts (neutropenic fever/grade (Gr) 3, pneumonia/Gr 3, 1 individual pt); cohort 2, DLT in 2 of 2 pts (neutropenic fever /Gr 3, 2 pts); cohort 3, DLT in 3 of 4 pts (neutropenic fever /Gr 3 and Gr 5, pulmonary embolism/ Gr 3, 3 pts). A pt in cohort 3 died from neutropenic fever and sepsis at cycle 3 despite dose modifications and growth factor support. Preliminary measures of efficacy by method of assessment and cohort assignment are summarized ( Table ).
CONCLUSIONS
We conclude that the cohort 1 dose level of D 75 mg/m2, R 2.5 mg, B 15 mg/kg is safe and demonstrates anti-cancer efficacy. Pt accrual continues at this dose level for the dose-expansion phase of the study. [Table: see text] No significant financial relationships to disclose.